drugset / Trial / NCT00083421

Effects of ONO-2506PO in Patients With Alzheimer's Disease

NCT00083421 ↗

Phase 2 Completed 647 enrolled Ono Pharma USA Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.

Timeline

Start
2004-06
Primary completion
—
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ARUNDIC ACID Small molecule — —

Indications